Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2010

Conditions

Healthy

Interventions

DRUG

BI 10773 XX (Trial Formulation 2)

one single dose tablet in the morning

DRUG

BI 10773 (Final Formulation)

one single film-coated tablet in the morning

Trial Locations (1)

1245.51.1 Boehringer Ingelheim Investigational Site, Biberach